Table 1.
Case | Target | Volume injected (nl) | Survival |
---|---|---|---|
1 | Ce | 200 PRV | 48 hr |
8 | Ce | 200 PRV | 52 hr |
26 | Ce | 200 PRV | 48 hr |
40 | Ce | 300 PRV | 48 hr |
46 | Ce | 200 PRV + 1% CTB | 48 hr |
47 | Ce | 200 PRV | 26 hr |
48 | Ce | 200 PRV | 82 hr |
49 | Ce | 200 PRV | 48 hr |
50 | Ce | 200 PRV | 96 hr |
51 | Lateral PB | 200 PRV + 1% CTB | 96 hr |
52 | Lateral PB | 200 PRV | 75 hr |
60 | Ce | 50 FG | 7 d |
61 | Ce | 40 FG | 7 d |
62 | Ce | 40 FG | 7 d |
67 | Ce | 40 FG | 7 d |
69 | Lateral PB | 50 PRV | 120 hr |
70 | Ce | 50 PRV | 72 hr |
71 | Ce | 40 FG (4%) | 7 d + 72 hr |
71 | Ce | 50 PRV | 72 hr |
85 | Right VPM | 200 PRV | 76 min |
85 | Left VPM | 200 PRV + 1 CTB | 27 min |
86 | Left VPM | 200 PRV + 1% CTB | 66 min |
86 | Right VPM | 200 PRV | 22 min |
87 | Left VPM | 100 PRV + 1% CTB | 65 hr |
88 | Left VPM | 100 PRV | 66 hr |
89 | Left VPM | 100 PRV | 77 hr |
91 | Left VPM | 100 PRV | 72 hr |
92 | Left VPM | 100 PRV | 72 hr |
93 | Ce | 100 PRV | 52 hr |
94 | Ce | 100 PRV | 52 hr |
95 | Ce | 100 PRV | 52 hr |
100 | Lateral PB | 40 CTB | 7 d + 72 hr |
100 | Ce | 100 PRV | 72 hr |
101 | Lateral PB | 40 CTB | 7 d + 96 hr |
101 | Ce | 100 PRV | 96 hr |
102 | Lateral PB | 40 CTB | 7 d + 48 hr |
102 | Ce | 100 PRV | 48 hr |
103 | Lateral PB | 80 PRV | 56 hr |
104 | Lateral PB | 80 PRV | 72 hr |
105 | Lateral PB | 80 PRV | 72 hr |
1501 | Ce | 200 PRV | 90 hr |
1508 | Ce | 200 PRV | 94 hr |
1510 | Ce | 200 PRV | 78.5 hr |
For all injections 20% of concentrated colloidal gold was added to each volume of PRV except when PRV was coinjected with CTB (cases 46, 85, 86, 87).
For cases 85, 86, 100, 101, and 102, FG or CTB were injected 7 d before PRV injection.
For cases 1501, 1508, and 1510, bilateral excitotoxic of the elPB were made 7 d before PRV injection.
Central nucleus of the amygdala (Ce); Cholera Toxin (CTB); Fluoro-Gold (FG); (PB) parabrachial; PRV, Bartha strain of pseudorables virus; VPM, ventroposteromedial nucleus of thalamus.